Novel cilengitide-based cyclic RGD peptides as αvβ₃ integrin inhibitors

Area of Science:

• Medicinal Chemistry
• Biochemistry
• Pharmacology

Background:

• Alpha-v beta-3 (αvβ₃) integrin is a key target in various diseases, including cancer.
• Cilengitide, a cyclic RGD peptide, is known for its selectivity towards αvβ₃ integrin.

Purpose of the Study:

• To synthesize and evaluate novel RGD-containing cyclic peptides as potent inhibitors of αvβ₃ integrin.
• To explore the impact of incorporating unnatural lipophilic amino acids into the cilengitide framework.

Main Methods:

• Solution-phase peptide synthesis.
• In vitro solid-phase binding assays to determine inhibitory potency (IC₅₀).
• Evaluation of binding behavior towards different integrin subtypes.

Main Results:

• Five new cyclic RGD peptides were successfully synthesized in high yield.
• Peptides demonstrated potent inhibition of αvβ₃ integrin, with IC₅₀ values as low as 3.3 nM.
• The incorporation of unnatural amino acids enhanced inhibitory activity.

Conclusions:

• Novel cyclic RGD peptides incorporating unnatural amino acids are potent inhibitors of αvβ₃ integrin.
• These findings support the potential of modifying the cilengitide scaffold for developing new therapeutics targeting αvβ₃ integrin.